Lecture, discussion, and case study presentation, assisted by computer generated visual effects, will be designed to assist the primary care provider with the early identification of patients at risk for target organ damage from hypertension, classes of antihypertensive medications designed to attenuate/avoid target organ damage, and mechanisms to evaluate impact of these medications and their potential adverse effects. Interactive case studies will enhance and cement the knowledge gleaned from the discussion and apply newest hypertension guidelines. 1.5 CE (1.50 Pharmacology) | $45

During this presentation learners will be engaged by this dynamic speaker on Abdominal trauma. Discussion will include the causes and how to evaluate and how to treat. Abdominal assessment and evaluation will be reviewed in detail. 1.0 CE/CME category 1 (0 Pharmacology) | $27.50

This talk will discuss the recognition, diagnosis and management of various abdominal emergencies. 1.0 CE/CME category 1 (0 Pharmacology) | $27.50

This interactive case-based discussion reviews the role of the Acute Care NP in recognizing and managing difficult airways of critically ill and injured patients. Airway assessment tools and positioning strategies are reviewed in detail. A variety of advanced airway tools are thoroughly examined, including pros and cons of each. Additionally, medications to aide in airway management are covered to equip the Acute Care NP knowledge to safely prescribe during the stressful situations of difficult airway management. 1.0 CE (0.50 Pharmacology) | $30

This session is a crash course into some of the newest ways to diagnose ACS, some new risk factors in women, new physical exam findings that can help you assess severity of heart disease and some new apps that are helpful in clinical medicine. 1.0 CE (0.25 Pharmacology) | $30

There has been a recent dramatic number of new pharmacological agents in the treatment of GI illnesses. In addition, there has been a dramatic change in how we use some existing medications. Are you ready for these changes? Please join Dr Peter Buch for a practical, case based, very interactive and FUN Update of GI Pharmacology that you will immediately put into use when you return to your practice settings. | 1.50 CE (1.50 Pharmacology) | $40

There has been a recent dramatic number of new pharmacological agents in the treatment of GI illnesses. In addition, there has been a dramatic change in how we use some existing medications. Are you ready for these changes? Please join Dr Peter Buch for a practical, case based, very interactive and FUN Update of GI Pharmacology that you will immediately put into use when you return to your practice settings. | 1.50 CE (1.50 Pharmacology) | $40

This session will provide information regarding the identification of women and men at risk for fracture based on bone densitometry and their 10-year fracture risk using the FRAX calculation. Pharmacologic therapies will be reviewed including patient selection for first line therapies when fracture risk is high and therapies for patients at very high risk including drug risks and benefits. Current controversies will be discussed including long-term use of bisphosphonates, adverse events including osteonecrosis of the jaw (ONJ) and atypical subtrocanteric femur fractures and drug holidays. New concerns about discontinuation of rank ligand inhibitors and the rapid increase in vertebral fractures will be discussed. Treatment of patients at high risk due to therapy such as aromatase inhibitors and androgen deprivation therapy will be presented. Case studies will be used to provide real clinical scenarios. | 1.0 CE/CME category 1 credits (0.75 Pharmacology) | $30

Cervical cancer prevention has changed significantly in recent years with less frequent screening and with the approval of HPV primary screening every 5 years, with a reflex Pap done only if the HPV test is positive. Additionally, co-testing with Pap and HPV every 5 years or Pap alone every 3 years remains an option. This session will review the appropriate use of Pap testing, the rationale for HPV testing along with the Pap (co-testing) in women 30 and older and the use of HPV testing as a primary screen (stand-alone test) in women 25 and older by two of the FDA approved HPV tests. There will be a discussion of the American Cancer Society Guidelines for screening and a review of the 2019 ASCCP Risk-Based Management Consensus Guidelines for management of abnormal screening and subsequent follow-up with case studies. These guidelines are a shift from results-based to risk-based management relative to the risk of an existing CIN 3 (pre-cancer). | 1.0 CE/CME category 1 credits (0 Pharmacology) | $27.50